Beneficial effects of perospirone on aggressive behavior associated with dementia

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 1, 2006, Pages 106-109

  Sato, Shinji ^a   Mizukami, Katsuyoshi ^b   Moro, Kazuo ^c   Tanaka, Yoshiro ^c   Asada, Takashi ^b  

^a Tsukuba Memorial Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Ishizaki Hospital   (Japan)

Author keywords

Aggressive behavior; Behavioral and Psychological Symptoms of Dementia; Dementia; Perospirone

Indexed keywords

PEROSPIRONE;

AGED; AGGRESSION; AGITATION; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PSYCHIATRIC DIAGNOSIS; SYMPTOMATOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MENTAL STATUS SCHEDULE; PSYCHOMOTOR AGITATION; THIAZOLES; TREATMENT OUTCOME;

EID: 33645216946     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01467.x     Document Type: Article

References (14)

1. Katz IR Jeste DV Mintzer JE Clyde C Napolitano J Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry 1999 60 107 115.
2. Onrust SV McClellan K. Perospirone. CNS Drugs 2001 15 329 337.
3. de Paulis T. Perospirone (Sumitomo Phamaceuticals). Curr. Opin. Investig. Drugs 2002 3 121 129.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn. American Psychiatric Press Washington, DC 1994.
5. Folstein MF Folstein SE McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians. J. Psychiatr. Res. 1975 12 189 198.
6. Reisberg B Borenstein J Salob SP Ferris SH Franssen E Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 1987 48 Suppl. 5 9 15.
7. Sato S Mizukami K Moro K et al. The effects of perospirone on behavioral and psychological symptoms of dementia (BPSD) in four dementia cases. Seishin lgaku 2004 46 415 417 (in Japanese).
8. Brodaty H Ames D Snowdon J et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J. Clin. Psychiatry 2003 64 134 143.
9. Street JS Clark WS Gannon KS et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2000 57 968 976.
10. Meehan KW Wang H David SR et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002 26 494 504.
11. Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J. Clin. Psychiatry 2001 62 Suppl. 21 23 25.
12. Oshimo T Shirakawa O Hatakoshi M Takashima M Ohta M Maeda K. Comparison of risperidone and perospirone for psychosis and behavioral disturbance associated with senile dementia. Jpn. J. Clin. Psyhcopharmacol. 2004 7 999 1006 (in Japanese).
13. Food and Drug Administration. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. (11 April 2005). Available from URL: http// http://www.fda.gov/cder/drug/advisory/ antipsychotic.htm (accessed 21 July 2005).
14. Liperoti R Gambassi G Lapane KL et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch. Intern. Med. 2005 165 696 701.